Literature DB >> 15114431

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects.

Chin B Eap1, Thierry Buclin, Elisabeth Hustert, Gabriela Bleiber, Kerry Powell Golay, Anne-Catherine Aubert, Pierre Baumann, Amalio Telenti, Reinhold Kerb.   

Abstract

OBJECTIVE: We investigated whether differences in pharmacokinetics of midazolam, a CYP3A probe, could be demonstrated between subjects with different CYP3A4 and CYP3A5 genotypes.
METHODS: Plasma concentrations of midazolam, and of total (conjugated + unconjugated) 1'OH-midazolam, and 4'OH-midazolam were measured after the oral administration of 7.5 mg or of 75 micro g of midazolam in 21 healthy subjects.
RESULTS: CYP3A5*7, CYP3A4*1E, CYP3A4*2, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*8, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17 and CYP3A4*18 alleles were not identified in the 21 subjects. CYP3A5*3, CYP3A5*6, CYP3A4*1B and CYP3A4*1F alleles were identified in 20, 1, 4 and 2 subjects, respectively. No statistically significant differences were observed for the AUC(inf) values between the different genotypes after the 75- micro g or the 7.5-mg dose.
CONCLUSION: Presently, CYP3A4 and CYP3A5 genotyping methods do not sufficiently reflect the inter-individual variability of CYP3A activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15114431     DOI: 10.1007/s00228-004-0767-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.

Authors:  Pei-Shan Shih; Jin-Ding Huang
Journal:  Drug Metab Dispos       Date:  2002-12       Impact factor: 3.922

3.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.

Authors:  D Dai; J Tang; R Rose; E Hodgson; R J Bienstock; H W Mohrenweiser; J A Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

Review 4.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

5.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

6.  Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP.

Authors:  Hossein Hamzeiy; Nasser Vahdati-Mashhadian; Helen J Edwards; Peter S Goldfarb
Journal:  Mutat Res       Date:  2002-03-20       Impact factor: 2.433

7.  Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

Authors:  T R Rebbeck; J M Jaffe; A H Walker; A J Wein; S B Malkowicz
Journal:  J Natl Cancer Inst       Date:  1998-08-19       Impact factor: 13.506

8.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Authors:  J Andrew Williams; Barbara J Ring; Varon E Cantrell; David R Jones; James Eckstein; Kenneth Ruterbories; Mitchell A Hamman; Stephen D Hall; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2002-08       Impact factor: 3.922

9.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

Authors:  J C Gorski; S D Hall; D R Jones; M VandenBranden; S A Wrighton
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

10.  CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.

Authors:  Raymond C Givens; Yvonne S Lin; Amy L S Dowling; Kenneth E Thummel; Jatinder K Lamba; Erin G Schuetz; Paul W Stewart; Paul B Watkins
Journal:  J Appl Physiol (1985)       Date:  2003-05-16
View more
  21 in total

1.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

Review 2.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  The recovery time-course of CYP3A after induction by St John's wort administration.

Authors:  Hiromitsu Imai; Tsutomu Kotegawa; Kimiko Tsutsumi; Takuya Morimoto; Nobuoki Eshima; Shigeyuki Nakano; Kyoichi Ohashi
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

5.  Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.

Authors:  Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-04       Impact factor: 2.745

6.  Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.

Authors:  Martin F Fromm; Helmut Schwilden; Iouri Bachmakov; Jörg König; Frank Bremer; Jürgen Schüttler
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

7.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.

Authors:  Akinbode Egbelakin; Michael J Ferguson; Emily A MacGill; Amalia S Lehmann; Ariel R Topletz; Sara K Quinney; Lang Li; Kevin C McCammack; Stephen D Hall; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2010-11-11       Impact factor: 3.167

8.  Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.

Authors:  Yingying Guo; Aroonrut Lucksiri; Gemma L Dickinson; Raj K Vuppalanchi; Janna K Hilligoss; Stephen D Hall
Journal:  Clin Pharmacol Ther       Date:  2019-09-12       Impact factor: 6.875

9.  Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Authors:  Eva Maria Staehli Hodel; Chantal Csajka; Frédéric Ariey; Monia Guidi; Abdunoor Mulokozi Kabanywanyi; Socheat Duong; Laurent Arthur Decosterd; Piero Olliaro; Hans-Peter Beck; Blaise Genton
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

10.  CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.

Authors:  Jodi L Skiles; ChienWei Chiang; Claire H Li; Steve Martin; Ellen L Smith; Gilbert Olbara; David R Jones; Terry A Vik; Saskia Mostert; Floor Abbink; Gertjan J Kaspers; Lang Li; Festus Njuguna; Tammy J Sajdyk; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2017-11-08       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.